Chicago Equity Partners LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 965 shares of the medical research company’s stock, valued at approximately $281,000.
Other large investors also recently made changes to their positions in the company. JJJ Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $25,000. Ellevest Inc. boosted its holdings in shares of Thermo Fisher Scientific by 137.5% during the second quarter. Ellevest Inc. now owns 95 shares of the medical research company’s stock worth $28,000 after purchasing an additional 55 shares during the period. American National Bank purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $29,000. Massey Quick Simon & CO. LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $30,000. Finally, Candriam Luxembourg S.C.A. boosted its holdings in shares of Thermo Fisher Scientific by 11.3% during the third quarter. Candriam Luxembourg S.C.A. now owns 104,069 shares of the medical research company’s stock worth $30,000 after purchasing an additional 10,569 shares during the period. 88.24% of the stock is currently owned by hedge funds and other institutional investors.
Shares of TMO opened at $294.65 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.80 and a quick ratio of 1.23. Thermo Fisher Scientific Inc. has a one year low of $208.34 and a one year high of $306.00. The company has a 50-day simple moving average of $290.14 and a two-hundred day simple moving average of $283.57. The firm has a market capitalization of $117.34 billion, a PE ratio of 26.50, a price-to-earnings-growth ratio of 1.90 and a beta of 1.14.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $2.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.88 by $0.06. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The business had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.19 billion. During the same period last year, the business posted $2.62 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 5.9% compared to the same quarter last year. Analysts expect that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 17th will be issued a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 47,729 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $295.88, for a total value of $14,122,056.52. Following the completion of the sale, the chief executive officer now directly owns 328,960 shares in the company, valued at $97,332,684.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jim P. Manzi sold 1,833 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the completion of the sale, the director now owns 28,592 shares of the company’s stock, valued at $7,803,614.56. The disclosure for this sale can be found here. Insiders sold 51,833 shares of company stock valued at $15,299,095 over the last 90 days. 0.45% of the stock is currently owned by company insiders.
TMO has been the subject of a number of analyst reports. Needham & Company LLC increased their target price on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Barclays set a $330.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Monday, July 15th. Credit Suisse Group reiterated a “buy” rating and set a $310.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. Finally, Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $305.00 to $319.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $314.45.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
See Also: What is the quiet period?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.